{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:06:33Z","timestamp":1784221593792,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T00:00:00Z","timestamp":1402617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"},{"start":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T00:00:00Z","timestamp":1402617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.38","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T13:31:39Z","timestamp":1402666299000},"page":"e219-e219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The novel immunotoxin HM1.24-ETA\u2032 induces apoptosis in multiple myeloma cells"],"prefix":"10.1038","volume":"4","author":[{"given":"M","family":"Staudinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Glorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Klausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Repp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Gramatzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,13]]},"reference":[{"key":"BFbcj201438_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962\u20132972.","journal-title":"Blood"},{"key":"BFbcj201438_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC . The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 2012; 30: 445\u2013452.","journal-title":"J Clin Oncol"},{"key":"BFbcj201438_CR3","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V90.8.3179","volume":"90","author":"S Ozaki","year":"1997","unstructured":"Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T . Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood 1997; 90: 3179\u20133186.","journal-title":"Blood"},{"key":"BFbcj201438_CR4","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood-2004-03-0890","volume":"104","author":"R Stein","year":"2004","unstructured":"Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004; 104: 3705\u20133711.","journal-title":"Blood"},{"key":"BFbcj201438_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008; 112: 1329\u20131337.","journal-title":"Blood"},{"key":"BFbcj201438_CR6","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","volume":"30","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960\u20131965.","journal-title":"J Clin Oncol"},{"key":"BFbcj201438_CR7","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840\u20131848.","journal-title":"J Immunol"},{"key":"BFbcj201438_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.imlet.2009.09.005","volume":"128","author":"JG van de Winkel","year":"2010","unstructured":"van de Winkel JG . Fc receptors: role in biology and antibody therapy. Immunol Lett 2010; 128: 4\u20135.","journal-title":"Immunol Lett"},{"key":"BFbcj201438_CR9","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood.V84.9.3017.3017","volume":"84","author":"VS Goldmacher","year":"1994","unstructured":"Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994; 84: 3017\u20133025.","journal-title":"Blood"},{"key":"BFbcj201438_CR10","first-page":"610","volume":"55","author":"YW Huang","year":"1995","unstructured":"Huang YW, Richardson JA, Vitetta ES . Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res 1995; 55: 610\u2013616.","journal-title":"Cancer Res"},{"key":"BFbcj201438_CR11","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","volume":"15","author":"H Ikeda","year":"2009","unstructured":"Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 2009; 15: 4028\u20134037.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201438_CR12","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","volume":"11","author":"P Sapra","year":"2005","unstructured":"Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005; 11: 5257\u20135264.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201438_CR13","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1182\/blood-2004-03-0963","volume":"104","author":"P Tassone","year":"2004","unstructured":"Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004; 104: 3688\u20133696.","journal-title":"Blood"},{"key":"BFbcj201438_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrd1957","volume":"5","author":"D Schrama","year":"2006","unstructured":"Schrama D, Reisfeld RA, Becker JC . Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5: 147\u2013159.","journal-title":"Nat Rev Drug Discov"},{"key":"BFbcj201438_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/nbt1141","volume":"23","author":"AM Wu","year":"2005","unstructured":"Wu AM, Senter PD . Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137\u20131146.","journal-title":"Nat Biotechnol"},{"key":"BFbcj201438_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/sj.leu.2403598","volume":"19","author":"ML Linenberger","year":"2005","unstructured":"Linenberger ML . CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19: 176\u2013182.","journal-title":"Leukemia"},{"key":"BFbcj201438_CR17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","volume":"29","author":"HA Burris 3rd","year":"2011","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29: 398\u2013405.","journal-title":"J Clin Oncol"},{"key":"BFbcj201438_CR18","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812\u20131821.","journal-title":"N Engl J Med"},{"key":"BFbcj201438_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.4161\/mabs.1.6.10029","volume":"1","author":"RJ Lutz","year":"2009","unstructured":"Lutz RJ, Whiteman KR . Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 2009; 1: 548\u2013551.","journal-title":"MAbs"},{"key":"BFbcj201438_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<269::AID-IJC18>3.0.CO;2-8","volume":"86","author":"M Azemar","year":"2000","unstructured":"Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 2000; 86: 269\u2013275.","journal-title":"Int J Cancer"},{"key":"BFbcj201438_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc1891","volume":"6","author":"I Pastan","year":"2006","unstructured":"Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ . Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6: 559\u2013565.","journal-title":"Nat Rev Cancer"},{"key":"BFbcj201438_CR22","first-page":"2848","volume":"62","author":"M Peipp","year":"2002","unstructured":"Peipp M, Kupers H, Saul D, Schlierf B, Greil J, Zunino SJ et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002; 62: 2848\u20132855.","journal-title":"Cancer Res"},{"key":"BFbcj201438_CR23","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","volume":"27","author":"RJ Kreitman","year":"2009","unstructured":"Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009; 27: 2983\u20132990.","journal-title":"J Clin Oncol"},{"key":"BFbcj201438_CR24","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","volume":"30","author":"RJ Kreitman","year":"2012","unstructured":"Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012; 30: 1822\u20131828.","journal-title":"J Clin Oncol"},{"key":"BFbcj201438_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jim.2011.06.023","volume":"371","author":"C Kellner","year":"2011","unstructured":"Kellner C, Bleeker WK, Lammerts van Bueren JJ, Staudinger M, Klausz K, Derer S et al. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. J Immunol Methods 2011; 371: 122\u2013133.","journal-title":"J Immunol Methods"},{"key":"BFbcj201438_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1034\/j.1600-0854.2003.00129.x","volume":"4","author":"S Kupzig","year":"2003","unstructured":"Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G . Bst-2\/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003; 4: 694\u2013709.","journal-title":"Traffic"},{"key":"BFbcj201438_CR27","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V84.6.1922.1922","volume":"84","author":"T Goto","year":"1994","unstructured":"Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, Solomon A et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994; 84: 1922\u20131930.","journal-title":"Blood"},{"key":"BFbcj201438_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.yexmp.2011.04.012","volume":"91","author":"DA Wainwright","year":"2011","unstructured":"Wainwright DA, Balyasnikova IV, Han Y, Lesniak MS . The expression of BST2 in human and experimental mouse brain tumors. Exp Mol Pathol 2011; 91: 440\u2013446.","journal-title":"Exp Mol Pathol"},{"key":"BFbcj201438_CR29","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00262-008-0612-4","volume":"58","author":"W Wang","year":"2009","unstructured":"Wang W, Nishioka Y, Ozaki S, Jalili A, Abe S, Kakiuchi S et al. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother 2009; 58: 967\u2013976.","journal-title":"Cancer Immunol Immunother"},{"key":"BFbcj201438_CR30","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/sj.onc.1209986","volume":"26","author":"YF Wong","year":"2007","unstructured":"Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC et al. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene 2007; 26: 1971\u20131982.","journal-title":"Oncogene"},{"key":"BFbcj201438_CR31","doi-asserted-by":"publisher","first-page":"13688","DOI":"10.1073\/pnas.1101684108","volume":"108","author":"E Erikson","year":"2011","unstructured":"Erikson E, Adam T, Schmidt S, Lehmann-Koch J, Over B, Goffinet C et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317\/BST-2\/HM1.24\/tetherin in humans. Proc Natl Acad Sci USA 2011; 108: 13688\u201313693.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201438_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.thj.6200075","volume":"2","author":"R Burger","year":"2001","unstructured":"Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W et al. Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001; 2: 42\u201353.","journal-title":"Hematol J"},{"key":"BFbcj201438_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783\u20131792.","journal-title":"Cancer Res"},{"key":"BFbcj201438_CR34","unstructured":"Peipp M, Ehlert C, Staudinger M, Kellner C, Burger R, Bruenke J et al. A recombinant bispecific antibody targeting HM1.24 for recruiting Fc\u03b3RIII-positive cytotoxic effector cells against multiple myeloma. (submitted)."},{"key":"BFbcj201438_CR35","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1128\/AEM.66.4.1572-1579.2000","volume":"66","author":"S Barth","year":"2000","unstructured":"Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A . Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. Appl Environ Microbiol 2000; 66: 1572\u20131579.","journal-title":"Appl Environ Microbiol"},{"key":"BFbcj201438_CR36","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.4049\/jimmunol.1201321","volume":"189","author":"C Kellner","year":"2012","unstructured":"Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW et al. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol 2012; 189: 5037\u20135046.","journal-title":"J Immunol"},{"key":"BFbcj201438_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ijc.24758","volume":"126","author":"A Guenther","year":"2010","unstructured":"Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010; 126: 239\u2013246.","journal-title":"Int J Cancer"},{"key":"BFbcj201438_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0022-1759(01)00298-8","volume":"251","author":"M Peipp","year":"2001","unstructured":"Peipp M, Simon N, Loichinger A, Baum W, Mahr K, Zunino SJ et al. An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells. J Immunol Methods 2001; 251: 161\u2013176.","journal-title":"J Immunol Methods"},{"key":"BFbcj201438_CR39","doi-asserted-by":"publisher","first-page":"15927","DOI":"10.1074\/jbc.M109.005124","volume":"284","author":"N Masuyama","year":"2009","unstructured":"Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A et al. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem 2009; 284: 15927\u201315941.","journal-title":"J Biol Chem"},{"key":"BFbcj201438_CR40","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1083\/jcb.200804154","volume":"184","author":"R Rollason","year":"2009","unstructured":"Rollason R, Korolchuk V, Hamilton C, Jepson M, Banting G . A CD317\/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. J Cell Biol 2009; 184: 721\u2013736.","journal-title":"J Cell Biol"},{"key":"BFbcj201438_CR41","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.4049\/jimmunol.157.4.1652","volume":"157","author":"JA Francisco","year":"1996","unstructured":"Francisco JA, Kiener PA, Moran-Davis P, Ledbetter JA, Siegall CB . Cytokine activation sensitizes human monocytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. J Immunol 1996; 157: 1652\u20131658.","journal-title":"J Immunol"},{"key":"BFbcj201438_CR42","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","volume":"17","author":"Y Nefedova","year":"2003","unstructured":"Nefedova Y, Landowski TH, Dalton WS . Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003; 17: 1175\u20131182.","journal-title":"Leukemia"},{"key":"BFbcj201438_CR43","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","volume":"15","author":"RF Alderson","year":"2009","unstructured":"Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 2009; 15: 832\u2013839.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201438_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.0105-2896.2009.00867.x","volume":"234","author":"W Cao","year":"2010","unstructured":"Cao W, Bover L . Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev 2010; 234: 163\u2013176.","journal-title":"Immunol Rev"},{"key":"BFbcj201438_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/eji.201242799","volume":"43","author":"JM Moffat","year":"2013","unstructured":"Moffat JM, Segura E, Khoury G, Caminschi I, Cameron PU, Lewin SR et al. Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. Eur J Immunol 2013; 43: 595\u2013605.","journal-title":"Eur J Immunol"},{"key":"BFbcj201438_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cellimm.2010.10.011","volume":"267","author":"H Yoo","year":"2011","unstructured":"Yoo H, Park SH, Ye SK, Kim M . IFN-gamma-induced BST2 mediates monocyte adhesion to human endothelial cells. Cell Immunol 2011; 267: 23\u201329.","journal-title":"Cell Immunol"},{"issue":"Pt 21","key":"BFbcj201438_CR47","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1242\/jcs.003343","volume":"120","author":"R Rollason","year":"2007","unstructured":"Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G . Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007; 120 (Pt 21): 3850\u20133858.","journal-title":"J Cell Sci"},{"key":"BFbcj201438_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1365-2141.2005.05869.x","volume":"133","author":"M Schwemmlein","year":"2006","unstructured":"Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006; 133: 141\u2013151.","journal-title":"Br J Haematol"},{"key":"BFbcj201438_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/BF02983378","volume":"78","author":"D Chauhan","year":"2003","unstructured":"Chauhan D, Hideshima T, Anderson KC . Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol 2003; 78: 114\u2013120.","journal-title":"Int J Hematol"},{"key":"BFbcj201438_CR50","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-0854.2006.00391.x","volume":"7","author":"DC Smith","year":"2006","unstructured":"Smith DC, Spooner RA, Watson PD, Murray JL, Hodge TW, Amessou M et al. Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum. Traffic 2006; 7: 379\u2013393.","journal-title":"Traffic"},{"key":"BFbcj201438_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJM200107263450402","volume":"345","author":"RJ Kreitman","year":"2001","unstructured":"Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241\u2013247.","journal-title":"N Engl J Med"},{"key":"BFbcj201438_CR52","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","volume":"18","author":"RJ Kreitman","year":"2000","unstructured":"Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622\u20131636.","journal-title":"J Clin Oncol"},{"key":"BFbcj201438_CR53","doi-asserted-by":"publisher","first-page":"11311","DOI":"10.1073\/pnas.0804851105","volume":"105","author":"M Onda","year":"2008","unstructured":"Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I . An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008; 105: 11311\u201311316.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201438_CR54","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","volume":"113","author":"JE Weldon","year":"2009","unstructured":"Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113: 3792\u20133800.","journal-title":"Blood"},{"key":"BFbcj201438_CR55","doi-asserted-by":"publisher","first-page":"18097","DOI":"10.1073\/pnas.1113694108","volume":"108","author":"RA Liberatore","year":"2011","unstructured":"Liberatore RA, Bieniasz PD . Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci USA 2011; 108: 18097\u201318101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201438_CR56","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2011-06-364521","volume":"119","author":"YT Tai","year":"2012","unstructured":"Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 2012; 119: 2074\u20132082.","journal-title":"Blood"},{"key":"BFbcj201438_CR57","unstructured":"Powles R, Yong K, Sirohi B . Humanized anti-HM1.24 antibody (AHM): phase I study in patients with relapsed or refractory myeloma. Japanese Multiple Myeloma Forum Proceedings, 3 November, 2003."},{"key":"BFbcj201438_CR58","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1182\/blood-2009-08-239004","volume":"115","author":"C Schliemann","year":"2010","unstructured":"Schliemann C, Roesli C, Kamada H, Borgia B, Fugmann T, Klapper W et al. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 2010; 115: 736\u2013744.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201438","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:51:49Z","timestamp":1672959109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,13]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,6]]}},"alternative-id":["BFbcj201438"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.38","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,13]]},"assertion":[{"value":"2 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}